Literature DB >> 25336115

Challenges in combining novel molecularly targeted agents in cancer medicine.

T A Yap1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25336115     DOI： 10.1093/annonc/mdu483

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Authors:  Alexander Drilon; Anne A Eaton; Katja Schindler; Mrinal M Gounder; David R Spriggs; Pamela Harris; S Percy Ivy; Alexia Iasonos; Mario E Lacouture; David M Hyman
Journal:  Cancer       Date:  2016-02-24       Impact factor: 6.860

2.  Dynamics of preventive vs post-diagnostic cancer control using low-impact measures.

Authors:  Andrei R Akhmetzhanov; Michael E Hochberg
Journal:  Elife       Date:  2015-06-25       Impact factor: 8.140
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.